TONSL Promotes Hepatocellular Carcinoma Progression by Inhibiting Apoptosis Through Homologous Recombination Repair
Cancer Science · 2026
DOI: 10.1111/cas.70386 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2026. Verfasst von Akinori Tsujimoto und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Kyushu University Beppu Hospital, Oita, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Apoptosis, Recombinational DNA Repair. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Princess Takamatsu Cancer Research Fund, Takeda Science Foundation, OITA Cancer Research Foundation.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is an extremely aggressive type of cancer with a poor prognosis and is often associated with amplification of chromosome 8q. Tonsoku‐like DNA repair protein (TONSL) gene, located on 8q, plays a role in repairing DNA double‐strand breaks. However, its functional relevance in HCC is not yet fully understood. In this study, we investigated the biological significance of TONSL in HCC progression. Analyses of public datasets and clinical specimens revealed that TONSL expression was markedly elevated in tumor tissues. TONSL levels showed a positive correlation with copy number variation and high levels were significantly associated with unfavorable patient outcomes. Functional assays demonstrated that TONSL knockout substantially reduced cell growth and increased apoptosis. Mechanistically, loss of TONSL impaired the recruitment of RAD51 to DNA damage sites, resulting in defective homologous recombination repair and enhanced apoptotic activity. Furthermore, TONSL‐knockout HCC cells showed increased sensitivity to poly (ADP‐ribose) polymerase (PARP) inhibitor. In a xenograft model, tumors generated from TONSL‐knockout cells exhibited significantly reduced growth, underscoring the importance of TONSL in promoting HCC progression. Collectively, these findings indicate that TONSL facilitates HCC development by supporting RAD51‐mediated DNA repair and suppressing apoptosis, and its elevated expression serves as a marker of poor prognosis. Thus, TONSL represents a promising biomarker of tumor aggressiveness and a potential therapeutic target in HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Kyushu University Beppu Hospital, Oita, Japan.
- Department of Surgery, Nara Medical University, Nara, Japan.
- Department of Breast and Endocrine Surgery, Kochi University, Kochi, Japan.
ORCID-Profile: Akinori Tsujimoto, Tomohiko Ikehara, Qingjiang Hu, Takaaki Masuda, Koshi Mimori
Förderung
- Princess Takamatsu Cancer Research Fund
- Takeda Science Foundation
- OITA Cancer Research Foundation
- Japan Society for the Promotion of Science
Zitieren
APA
Tsujimoto, A., Otsu, H., Ofuchi, T., Ikehara, T., Hirose, K., Shibuta, S., Omachi, K., Takahashi, Y., Ono, Y., Higuchi, S., Tatsumi, T., Hosoda, K., Hu, Q., Yonemura, Y., Masuda, T., Sho, M., & Mimori, K. (2026). TONSL Promotes Hepatocellular Carcinoma Progression by Inhibiting Apoptosis Through Homologous Recombination Repair. Cancer Science. https://doi.org/10.1111/cas.70386
Vancouver
Tsujimoto A, Otsu H, Ofuchi T, Ikehara T, Hirose K, Shibuta S, et al. TONSL Promotes Hepatocellular Carcinoma Progression by Inhibiting Apoptosis Through Homologous Recombination Repair. Cancer Science. 2026. doi:10.1111/cas.70386
BibTeX
@article{Tsujimoto2026,
author = {Tsujimoto, Akinori and Otsu, Hajime and Ofuchi, Takashi and Ikehara, Tomohiko and Hirose, Kosuke and Shibuta, Shohei and Omachi, Kazuki and Takahashi, Yu and Ono, Yuya and Higuchi, Satoshi and Tatsumi, Takanari and Hosoda, Kiyotaka and Hu, Qingjiang and Yonemura, Yusuke and Masuda, Takaaki and Sho, Masayuki and Mimori, Koshi},
title = {TONSL Promotes Hepatocellular Carcinoma Progression by Inhibiting Apoptosis Through Homologous Recombination Repair},
journal = {Cancer Science},
year = {2026},
doi = {10.1111/cas.70386}
}
EUVIMED